Advertisement
ADPT vs AXON
Which Stock Would AI Choose? Adaptive Biotechnologies (ADPT) vs. Axon Enterprise (AXON) Stock Comparison
Key Takeaways
- ADPT, a biotech firm focused on immune diagnostics, shows strong year-to-date gains of 12.13% and a remarkable 93.89% one-year return, driven by minimal residual disease (MRD) testing momentum.
- AXON, a leader in public safety technology, boasts a larger market cap of $32.4 billion but has faced a roughly 29% year-to-date decline amid market volatility.
- Recent revenue growth highlights ADPT's 55% quarterly jump and AXON's 33% trailing twelve months (TTM) increase, signaling robust demand in healthcare and law enforcement sectors.
- AXON demonstrates profitability with positive EPS (earnings per share) of $1.53 TTM, contrasting ADPT's ongoing losses at -$0.39 TTM.
- Both stocks reflect innovation—ADPT in immune medicine and AXON in AI-enhanced public safety—but differ in risk profiles and sector exposures.
- Investor sentiment leans toward growth potential, with AXON projecting 27-30% revenue growth in 2026 despite recent pullbacks.
Introduction
This comparison pits ADPT against AXON, two innovative publicly traded companies navigating distinct market landscapes. Adaptive Biotechnologies advances immune-driven diagnostics and therapeutics in healthcare, while Axon Enterprise dominates public safety with hardware, software, and emerging AI tools. Traders seeking high-growth opportunities in biotech or technology, and investors eyeing relative performance amid volatility, will find value here. By examining recent momentum, financials, and sector dynamics, this analysis illuminates stock positioning in the current environment, aiding informed decision-making without speculation.
ADPT Overview and Recent Performance
Adaptive Biotechnologies Corporation (ADPT) specializes in decoding the adaptive immune system for diagnostics like clonoSEQ, an FDA-approved assay for MRD (minimal residual disease) monitoring in blood cancers, and research tools. In recent market activity, the stock has traded around $14.27, with a market cap of $2.28 billion, 52-week range of $8.38-$20.76, and no PE ratio due to losses. Year-to-date returns stand at 12.13%, with one-year gains of 93.89%, reflecting positive sentiment from Q4 2025 revenue beats at $71.68 million (up significantly) and raised MRD volume guidance to 30%+ growth. Insider sales and upcoming Q1 2026 earnings on May 5 have introduced caution, yet partnerships like Pfizer bolster long-term prospects. Biotech volatility and clinical catalysts have driven recent price strength.
AXON Overview and Recent Performance
Axon Enterprise, Inc. (AXON) develops conducted energy weapons (e.g., TASERs), body-worn cameras, cloud-based evidence management, and AI solutions for public safety. The stock recently closed near $402.31, with a $32.4 billion market cap, 52-week range of $339.01-$885.92, and elevated PE ratio of 262.95 reflecting growth pricing. Despite strong Q4 2025 revenue of $796.72 million and 40% software/services growth, shares have declined about 29% year-to-date amid broader pullbacks. Recent weeks highlight AI innovations like 911 call co-pilots and debt concerns, contributing to volatility. Anticipated 27-30% 2026 revenue expansion supports resilience, with TTM revenue at $2.78 billion fueling positive analyst views despite short-term weakness.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of 25 top-performing AI trading bots from over 351 available, each designed to trade thousands of tickers across diverse strategies. These bots excel in current market conditions, featuring annualized returns ranging from 23.53% to 163.10%, win rates of 51.30% to 88.33%, and profit factors up to 11.70. Styles vary from short-term 5-60 minute trend traders using technical analysis to swing traders over 1-49 days incorporating take-profit/stop-loss corridors and fundamental insights. Focused on high-growth areas like semiconductors, AI infrastructure, and space, they offer real-time signals for copy trading with robust risk management. Traders can explore these to align bots with their timeframe and risk tolerance.
Head-to-Head Comparison
ADPT and AXON diverge sharply in business models: ADPT’s biotech platform targets immune diagnostics with high R&D intensity, while AXON blends hardware sales with recurring software revenue (e.g., Evidence.com subscriptions). Growth drivers include ADPT’s MRD expansion versus AXON’s AI integrations in public safety. Recent momentum favors ADPT’s steady uptrend against AXON’s dip, but AXON offers scale and profitability. Risks skew higher for ADPT (clinical/regulatory hurdles) than AXON (debt, competition). Sector-wise, healthcare volatility contrasts industrials stability; sentiment tilts toward AXON’s moat amid AI tailwinds.
Tickeron AI Verdict
Tickeron’s AI currently favors AXON over ADPT, citing superior trend consistency in long-term growth, financial stability with positive EPS, and catalysts like AI public safety expansions despite recent dips. ADPT’s momentum is compelling, but AXON’s larger positioning and projected revenue acceleration suggest higher probability of outperformance in volatile conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADPT is a Buy and AXON is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADPT’s FA Score shows that 0 FA rating(s) are green whileAXON’s FA Score has 0 green FA rating(s).
- ADPT’s FA Score: 0 green, 5 red.
- AXON’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADPT’s TA Score shows that 5 TA indicator(s) are bullish while AXON’s TA Score has 5 bullish TA indicator(s).
- ADPT’s TA Score: 5 bullish, 5 bearish.
- AXON’s TA Score: 5 bullish, 4 bearish.
Price Growth
ADPT (@Medical Specialties) experienced а +14.80% price change this week, while AXON (@Aerospace & Defense) price change was -7.67% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.17%. For the same industry, the average monthly price growth was +15.03%, and the average quarterly price growth was -5.68%.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -5.94%. For the same industry, the average monthly price growth was -1.22%, and the average quarterly price growth was +14.24%.
Reported Earning Dates
ADPT is expected to report earnings on Aug 05, 2026.
AXON is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Medical Specialties (-1.17% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Aerospace & Defense (-5.94% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
| ADPT | AXON | ADPT / AXON | |
| Capitalization | 2.78B | 36.5B | 8% |
| EBITDA | -20.94M | 320M | -7% |
| Gain YTD | 7.020 | -20.323 | -35% |
| P/E Ratio | N/A | 182.46 | - |
| Revenue | 295M | 2.98B | 10% |
| Total Cash | 218M | 737M | 30% |
| Total Debt | 77.6M | 1.83B | 4% |
ADPT | AXON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 44 Fair valued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 63 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 40 | 58 | |
P/E GROWTH RATING 1..100 | 100 | 56 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ADPT's Valuation (44) in the Hospital Or Nursing Management industry is somewhat better than the same rating for AXON (80) in the Biotechnology industry. This means that ADPT’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (63) in the Biotechnology industry is somewhat better than the same rating for ADPT (100) in the Hospital Or Nursing Management industry. This means that AXON’s stock grew somewhat faster than ADPT’s over the last 12 months.
AXON's SMR Rating (100) in the Biotechnology industry is in the same range as ADPT (100) in the Hospital Or Nursing Management industry. This means that AXON’s stock grew similarly to ADPT’s over the last 12 months.
ADPT's Price Growth Rating (40) in the Hospital Or Nursing Management industry is in the same range as AXON (58) in the Biotechnology industry. This means that ADPT’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for ADPT (100) in the Hospital Or Nursing Management industry. This means that AXON’s stock grew somewhat faster than ADPT’s over the last 12 months.
| ADPT | AXON | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 62% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 87% | 2 days ago 77% |
| MACD ODDS (%) | 2 days ago 90% | N/A |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 67% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 72% |
| Advances ODDS (%) | 7 days ago 82% | 9 days ago 74% |
| Declines ODDS (%) | 3 days ago 87% | 2 days ago 69% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 71% |
Advertisement